In the USPSTF's final recommendation statement in JAMA,
other recommendations are largely unchanged. Women aged 35 years and
older who are at increased risk for breast cancer can be offered
medications, also including tamoxifen and raloxifene, if they are at low
risk for side effects (grade B recommendation). Clinicians can use
widely available risk assessment tools or combinations of risk factors
(e.g., age 65 years or older with a first-degree relative with breast
cancer) to determine a patient's eligibility.
The task force continues to recommend against routinely using such medications in women who aren't at increased risk (grade D).
No comments:
Post a Comment